Table 3.
Recent reports on outcomes in patients with hepatocellular carcinoma (HCC) accompanied by portal vein tumour thrombus
| Author(s) | Published | Setting | Patients (Vp3 and Vp4), n | Median survival, months | 5-year survival, % (Kaplan-Meier) | 5-year survivors, n |
|---|---|---|---|---|---|---|
| Ikai et al.5 | 2006 | HCC with MPVTT (Vp3 and Vp4) | 78 | 6.9 | 10.9% | 4 |
| Le Treut et al.6 | 2006 | Tumour thrombus in portal and hepatic veins (n = 26) | 22 | 9.0 | 17.0% | 2 |
| Kondo et al.7 | 2009 | HCC with MPVTT (Vp1–4, n = 48) | 29 | 11.3 | 0% (only Vp4) | 0 |
| Ban et al.8 | 2009 | HCC with MPVTT (Vp3 and Vp4) | 45 | 20.0 | 22.4% | 3 |
| Shi et al.9 | 2010 | HCC with MPVTT (Vp1–4, n = 406) | 98 | 6.4 | 0% (only Vp4) | 0 |
| Present study | 2011 | HCC with MPVTT (Vp3 and Vp4) | 29 | 16.9 | 17.2% | 5 |
Vp3, first branch of the portal vein; Vp4, main portal trunk or the opposite portal branch.